OneMedNet Reports Preliminary Revenue for Third Quarter 2026 and Fourth Quarter 2026 Outlook

The fourth-quarter revenue forecast depends on customers accepting delivered data by quarter-end.

Rhea-AI Summary

OneMedNet (ONMD) expects approximately $1 million in preliminary third-quarter 2026 revenue and issued a fourth-quarter revenue forecast. For the quarter ended September 30, 2026, expected revenue represents a 242% increase from the quarter ended June 30, 2026, and a 465% increase from the prior-year quarter.

The company forecasts approximately $12 million to $14 million in fourth-quarter 2026 revenue, pending anticipated customer acceptance of delivered data by quarter-end. OneMedNet said it began delivering on its growing sales funnel at scale during the third quarter, with order timing and scaled delivery weighting revenue toward the fourth quarter. Third-quarter figures remain preliminary and subject to finalization and adjustment during preparation of the quarterly report, which the company expects to release by November 16, 2026.

3 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter 2026 revenue guidance targets approximately $12 million to $14 million.
• Moderate pointPreliminary third-quarter 2026 revenue of approximately $1 million rose 242% sequentially and 465% year over year.
• Minor pointSales-funnel delivery began at scale during third-quarter 2026, supporting the company's stated fourth-quarter revenue pace.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Fourth-quarter revenue guidance depends on anticipated customer acceptance of delivered data by quarter-end.
• Minor point. Forward-looking: it has not happened yet and may not happen.Third-quarter 2026 revenue remains preliminary and subject to finalization and adjustment during quarterly-report preparation.

Key Figures

Preliminary Q3 revenue: Approximately $1 million Quarter-over-quarter revenue growth: 242% Year-over-year revenue growth: 465% +2 more

Preliminary Q3 revenue

Approximately $1 million

Quarter ended September 30, 2026

Quarter-over-quarter revenue growth

242%

Q3 2026 vs. Q2 2026

Year-over-year revenue growth

465%

Q3 2026 vs. Q3 2025

Q4 revenue guidance

Approximately $12 million to $14 million

Q4 2026; pending anticipated customer acceptance of delivered data

Expected Form 10-Q release

By November 16, 2026

Finalization and adjustment of preliminary Q3 results

Key Terms

real-world data, de-identification, form 10-q

3 terms

real-world data medical

"provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data"

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

de-identification technical

"our building of our de-identification pipeline and delivery infrastructure to scale with demand"

The process of removing or altering personal identifiers from a dataset so individuals cannot reasonably be identified. In regulated settings (for example under HIPAA) de-identification can be achieved by removing specified direct identifiers or by a qualified expert’s determination that the risk of re-identification is very small; common techniques include deleting names and ID numbers, masking or generalizing dates and locations, and applying statistical or cryptographic transformations to quasi‑identifiers. De-identified data is treated differently than identifiable personal data under many laws and policies, but it is not risk-free: re-identification can occur if remaining details are combined with other information.

form 10-q regulatory

"preparation of the Company’s Quarterly Report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MINNEAPOLIS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced preliminary revenue results for the third quarter ended September 30, 2026, and provides revenue guidance for the fourth quarter of 2026.

The Company expects to report revenue of approximately $1 million for the quarter ended September 30, 2026, representing a 242% increase from the prior quarter ended June 30, 2026, and a 465% increase from the prior-year quarter ended September 30, 2025. The Company also forecasts revenue of approximately $12 million to $14 million for the fourth quarter of 2026, pending the anticipated acceptance of delivered data by customers.

OneMedNet’s sales funnel has grown substantially over the course of 2026, and the Company began delivering on that funnel at scale during the third quarter of 2026. Consistent with order timing combined with scaled delivery, 2026 revenue is weighted to occur at a faster pace in the fourth quarter of 2026.

Our financial momentum reflects the Company’s First-Party (Direct-from-Source) multi-modal data sourced directly from its healthcare provider partners, not intermediaries or secondary markets, and the scaling of its de-Identified pipeline and delivery infrastructure, which de-identifies each study at the source while preserving the diagnostic fidelity its customers require.

“Our sales funnel has grown substantially this year, and we are now delivering on it,” said Aaron Green, President & CEO of OneMedNet. “The hardest work in this business; curating, de-identifying, and delivering regulatory-grade multimodal data at scale, is substantially complete. We are now able to get our product in our customers’ hands with the ability to convert the sales to revenue. Our anticipated revenue pace in the fourth quarter of 2026 is expected for two reasons: our data coming direct from our healthcare provider partners, and our building of our de-identification pipeline and delivery infrastructure to scale with demand. “

Third Quarter Preliminary Revenue and Fourth Quarter Outlook Highlights

• Preliminary third quarter 2026 revenue of approximately $1 million. Consistent with previously communicated delivery timing.
• Fourth quarter 2026 revenue guidance of approximately of $12 million to $14 million, pending anticipated customer acceptance of delivered data by quarter-end.

Third quarter 2026 revenue results are preliminary and are subject to finalization and adjustment in connection with the preparation of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, which we expect to release by November 16, 2026.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real-World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding our preliminary results for third of 2026, our revenue outlook for the fourth quarter of 2026, the timing of revenue recognition, the anticipation of data delivery and customer acceptance, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include but are not limited to our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary revenue does OneMedNet expect for the third quarter of 2026?

OneMedNet expects approximately $1 million in revenue for the quarter ended September 30, 2026. That represents a 242% increase from the quarter ended June 30, 2026, and a 465% increase from the prior-year quarter. The figures remain preliminary and subject to finalization and adjustment.

What is OneMedNet's fourth-quarter 2026 revenue guidance?

OneMedNet forecasts approximately $12 million to $14 million in fourth-quarter 2026 revenue, pending anticipated customer acceptance of delivered data by quarter-end. The company attributes the expected revenue pace to order timing and scaled delivery.